Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Dan’s practice focuses primarily on venture finance, securities law and offerings, mergers and acquisitions, and general business and corporate law, primarily for life sciences and technology companies.
VCs, strategic investors, and issuers rely on Dan’s extensive experience in private fund raising, including equity and debt financings. Public companies also turn to him in connection with public and private offerings and their securities law and compliance needs. In addition, both buyers and sellers engage Dan to counsel them in complicated mergers and acquisitions. Dan also regularly advises both private and public companies at various stages of development on general corporate matters.
Prior to joining the firm, Dan served as a law clerk to the justices of the Superior Court of Massachusetts. While in law school, he served as a staff author and comment editor for the Suffolk University Law Review.
Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Experience
Offerings for Public Companies
- Represented Vertex Pharmaceuticals (Nasdaq: VRTX) in over $2.0 billion in equity and debt offerings since 2006
- Represented ImmunoGen (Nasdaq: IMGN) in approximately $350 million in equity offerings since 2008
- Represented Amedica (Nasdaq: AMDA) in its IPO
- Represented the underwriters in the IPO of Calithera Biosciences (Nasdaq: CALA)
- Represented the underwriters in the IPO of American Depositary Shares of GW Pharmaceuticals (Nasdaq: GWPH) and two additional follow-on offerings
Venture Capital & Strategic Financings
- Represented a public technology company in the semiconductor and life sciences industry (Nasdaq) in multiple strategic investments
- Represented a public medical device company (NYSE) in multiple strategic investments
- Represented Clarus Ventures in its investments in Ophthotech (Nasdaq: OPHT), VBI Vaccines (Nasdaq: VBIV), TyRx Pharma, and Link Medicine
- Represented a public biotechnology company (Nasdaq) in its strategic equity investment in a private biotechnology company
- Represented Style Me Pretty in its strategic investment from AOL (NYSE: AOL)
- Represented Synchroneuron in multiple equity financings
- Represented TransMolecular in multiple equity and debt financings
- Represented Ion Torrent Systems in multiple equity financings
- Represented I-Pulse in multiple equity financings
- Represented TransForm Pharmaceuticals in multiple equity financings
- Represented Hemera Biosciences in its Series A financing
Mergers & Acquisitions
- Represented Brooks Automation (Nasdaq: BRKS) in its purchase of BioStorage Technologies
- Represented a public biotechnology company (Nasdaq) in its entering into a merger option to acquire a private biotechnology company
- Represented Clarus Ventures in the reverse merger of VBI Vaccines (Nasdaq: VBIV) with Paulson Capital
- Represented Orchid BioSciences (Nasdaq: ORCH) in its sale to Laboratory Corporation of America (NYSE: LH)
- Represented QIAGEN (Nasdaq: QGEN) in its purchase of SA Biosciences
- Represented TransMolecular in its sale to Morphotek (a subsidiary of Eisai Co. (Tokyo Stock Exchange))
- Represented Auspice in its sale to the ARRIS Group (Nasdaq: ARRS)
- Represented EPIX Pharmaceuticals (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals
- Represented TransForm Pharmaceuticals in its sale to Johnson & Johnson (NYSE: JNJ)
- Represented FastClick (Nasdaq: FSTC) in its sale to ValueClick (Nasdaq: VCLK)
viewpoints
NYSE and Nasdaq Propose Delayed Effectiveness of Compensation “Clawback” Listing Standards
June 9, 2023 | Alert | By Anne Bruno, Daniel T. Kajunski
Read about the proposal by NYSE and Nasdaq to delay the effective date of the SEC’s clawback listing standards to October 2, 2023.
SEC Adopts New Share Repurchase Disclosure Rules
May 18, 2023 | Alert | By Daniel T. Kajunski, Hannah L. Karraker
Read about the SEC’s final rules requiring increased quantitative data and expanded narrative disclosure regarding share repurchases by an issuer.
SEC Adopts Pay Versus Performance Compensation Disclosure Requirements
September 26, 2022 | Advisory | By Xandy Walsh, Anne Bruno, Daniel T. Kajunski
Read about the SEC’s recently adopted rules to require reporting companies to disclose the so-called Pay Versus Performance relationship between a company’s financial performance and executive compensation that was “actually paid” by the company over a five-year period.
Time to Evaluate Your Filer Status for Next Year
July 26, 2022 | Advisory | By Daniel T. Kajunski
Preparation for 2021 Fiscal Year-End SEC Filings and 2022 Annual Shareholder Meetings
January 18, 2022 | Advisory | By Megan Gates, John Condon, Anne Bruno, Melanie Ruthrauff Levy, Daniel T. Kajunski, Cynthia Larose, Breton Leone-Quick, Page R. Hubben
NYSE Amends Related Party Transaction Approval Rule
May 27, 2021 | Advisory | By Daniel T. Kajunski
NYSE Amends Shareholder Approval Rules
May 26, 2021 | Advisory | By Daniel T. Kajunski
SEC Amends MD&A and Other Financial Disclosure Rules
February 5, 2021 | Alert | By Daniel T. Kajunski, Amanda Mei
Preparation for 2020 Fiscal Year-End SEC Filings and 2021 Annual Shareholder Meetings
January 21, 2021 | Advisory | By Megan Gates, John Condon, Daniel T. Kajunski, Anne Bruno
Nasdaq Proposes New Listing Rules Regarding Board Diversity
December 3, 2020 | Advisory | By Daniel T. Kajunski
News & Press
Twenty-Eight Mintz Attorneys Named To Boston Magazine’s Top Lawyers List
November 22, 2022
In its second annual edition, 28 Mintz attorneys were named to Boston Magazine’s Top Lawyers list.
Mintz Represents ImmunoGen, Inc. in $200 Million Transaction
April 14, 2015
Events & Speaking
Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Recognition & Awards
Boston Magazine Top Lawyers – Corporate Law (2021)
Recent Insights
SEC Approves Nasdaq Rule Change on Reverse Stock Splits and Minimum Bid Price Compliance Timing
October 17, 2024| Alert|
